Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Kharfan Dabaja, Mohamed A ^a,b   Hamadani, Mehdi ^c   Reljic, Tea ^d   Nishihori, Taiga ^a   Bensinger, William ^e   Djulbegovic, Benjamin ^a,d   Kumar, Ambuj ^a,d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Autologous hematopoietic stem cell transplantation; Multiple myeloma; Systematic review

Indexed keywords

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CLINICAL PROTOCOL; COMPARATIVE STUDY; EVENT FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENTION TO TREAT ANALYSIS; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; META-ANALYSIS AS TOPIC; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84871732121     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-2     Document Type: Article

References (35)

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe francais du myelome. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, et al. N Engl J Med 1996 335 91 97 10.1056/NEJM199607113350204 8649495 (Pubitemid 26240110)
2. Improved survival in multiple myeloma and the impact of novel therapies. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al. Blood 2008 111 2516 2520 10.1182/blood-2007-10-116129 17975015
3. A phase 2 study of bortezomib in relapsed, refractory myeloma. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. N Engl J Med 2003 348 2609 2617 10.1056/NEJMoa030288 12826635 (Pubitemid 36741588)
4. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, et al. Blood 2002 100 3063 3067 10.1182/blood-2002-03-0996 12384400 (Pubitemid 35217050)
5. Antitumor activity of thalidomide in refractory multiple myeloma. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al. N Engl J Med 1999 341 1565 1571 10.1056/NEJM199911183412102 10564685
6. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, et al. Blood 1999 93 55 65 9864146 (Pubitemid 29019388)
7. Single versus double autologous stem-cell transplantation for multiple myeloma. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, et al. N Engl J Med 2003 349 2495 2502 10.1056/NEJMoa032290 14695409 (Pubitemid 38010075)
8. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B, J Natl Cancer Inst 2009 101 100 106 10.1093/jnci/djn439 19141779
9. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G, J Clin Oncol 2002 20 1295 1303 10.1200/JCO.20.5.1295 11870172 (Pubitemid 34177436)
10. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European group for blood and marrow transplantation centres. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, Blade J, Cornelissen J, de Laurenzi A, Facon T, et al. Br J Haematol 2001 113 209 216 10.1046/j.1365-2141.2001.02726.x 11360893 (Pubitemid 32423325)
11. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, et al. Blood 2011 118 1979 1988 10.1182/blood-2011-02-337329 21690560
12. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Armeson KE, Hill EG, Costa LJ, Bone Marrow Transplant 2012 22964593
13. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, et al. Lancet Oncol 2011 12 1195 1203 10.1016/S1470- 2045(11)70243-1 21962393
14. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, et al. J Clin Oncol 2011 29 3016 3022 10.1200/JCO.2010.32.7312 21730266
15. A comparison of allografting with autografting for newly diagnosed myeloma. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omede P, Baldi I, et al. N Engl J Med 2007 356 1110 1120 10.1056/NEJMoa065464 17360989 (Pubitemid 46425595)
16. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma-an interim analysis of the german DSMM V trial. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou R, Metzner B, Peest D, Aulitzky W, Wandt H, et al. Blood 2011 114 51
17. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Rosiñol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla J, Hernandez B, Garcia-Frade J, et al. Blood 2008 112 3591 3593 10.1182/blood-2008-02-141598 18612103
18. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, Carnevale-Schianca F, Festuccia M, Brunello L, Omede P, et al. Blood 2011 117 6721 6727 10.1182/blood-2011-03-339945 21490341
19. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, et al. Blood 2006 107 3474 3480 10.1182/blood-2005-09- 3869 16397129
20. Donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50/54 study. Lokhorst H, Sonneveld P, Holt B, Oers M, Raymakers R, Zweegman S, Minnema M, Zijlmans M, Blood 2008 112 461 10.1182/blood-2007-09-077438 18650461
21. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D, Br J Haematol 1998 102 1115 1123 10.1046/j.1365-2141.1998.00930.x 9753033 (Pubitemid 28435189)
22. International uniform response criteria for multiple myeloma. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al. Leukemia 2006 20 1467 1473 10.1038/sj.leu. 2404284 16855634 (Pubitemid 44264086)
23. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, N Engl J Med 2003 348 1875 1883 10.1056/NEJMoa022340 12736280 (Pubitemid 36532313)
24. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, et al. J Clin Oncol 2007 25 2434 2441 10.1200/JCO.2006.10.2509 17485707 (Pubitemid 46999214)
25. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the dutch cooperative group HOVON 24 trial. Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, et al. Haematologica 2007 92 928 935 10.3324/haematol.11168 17606443 (Pubitemid 350144239)
26. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myelome. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, et al. Blood 2007 109 3489 3495 10.1182/blood-2006-08-040410 17209057 (Pubitemid 46572539)
27. Is there a future for auto-allo HSCT in multiple myeloma? Dispenzieri A, Lancet Oncol 2011 12 1176 1177 10.1016/S1470-2045(11)70258-3 21962392
28. Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, et al. Mayo Clin Proc 2007 82 323 341 17352369 (Pubitemid 46348934)
29. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, et al. Mayo Clin Proc 2009 84 1095 1110 10.4065/mcp.2009.0603 19955246
30. Practical methods for incorporating summary time-to-event data into meta-analysis. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, Trials 2007 8 16 10.1186/1745-6215-8-16 17555582 (Pubitemid 47161711)
31. Stuart A, Ord K, Kendall′s advanced theory of statistics Wiley 1994 23316283
32. Higgins JPT, Green S, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 edition The Cochrane Collaboration 2011
33. RevMan: Review Manager, The Cochrane Collaboration-available on the world wide web 51st http://www.cochrane.org/cochrane/revman.htm
34. StatsDirect Ltd, StatsDirect statistical software England: Stats Direct Ltd 2008 http://www.statsdirect.com
35. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D, J Clin Epidemiol 2009 62 1 34 10.1016/j.jclinepi.2009.06.006 19631507